J Clin Oncol 2008, 26:2442–2449.PubMedCrossRef 21. Sugio K, Uramoto H, Onitsuka T, Mizukami M, Ichiki Y, Sugaya M, Yasuda M, Takenoyama M, Oyama T, Hanagiri T, Yasumoto Z-VAD-FMK chemical structure K: Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations. Lung Cancer 2009, 64:314–318.PubMedCrossRef 22. Douillard JY, Shepherd FA, Hirsh V, Mok T, Socinski MA, Gervais R, Liao ML, Bischoff H, Reck M, Sellers MV, Watkins CL, Speake G, Armour AA, Kim ES: Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell

lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol 2010, 28:744–752.PubMedCrossRef 23. Mu XL, Li LY, Zhang XT, Wang MZ, Feng RE, Cui QC, Zhou HS, Guo BQ: Gefitinib-Sensitive Mutations

of the Epidermal Growth Factor Receptor Tyrosine Kinase Domain in Chinese Patients selleck chemicals with Non-Small Cell Lung Cancer. Clin Cancer Res 2005, 11:4289–4294.PubMedCrossRef 24. Tiseo M, Rossi G, Capelletti M, Sartori G, Spiritelli E, Marchioni A, Bozzetti C, De Palma G, Lagrasta C, Campanini N, Camisa R, Boni L, Franciosi V, Rindi G, Ardizzoni A: Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): study of a comprehensive panel of molecular markers. Lung Cancer 2010, 67:355–360.PubMedCrossRef 25. Ma F, Sun T, Shi Y,

Yu D, Tan W, Yang M, Wu C, Chu D, Sun Y, Xu B, Lin D: Polymorphisms of EGFR predict clinical outcome in advanced non-small-cell lung cancer patients treated with Gefitinib. Lung Cancer 2009, 66:114–119.PubMedCrossRef 26. Jian G, Songwen Z, Ling Z, Qinfang D, Jie Z, Liang T, Caicun Z: Prediction of epidermal growth factor receptor mutations in the plasma/pleural effusion to efficacy of gefitinib treatment in advanced non-small cell lung cancer. J Cancer Res Clin Oncol 2010,136(9):1341–7.PubMedCrossRef 27. Yamaguchi H, Soda H, Nakamura Y, Takasu M, Tomonaga N, Nakano H, Doi S, Nakatomi K, Nagashima S, Takatani H, Fukuda M, Hayashi T, Tsukamoto K, VAV2 Kohno S: Serum levels of surfactant protein D predict the anti-tumor activity of gefitinib in patients with advanced non-small cell lung cancer. Cancer Chemother Pharmacol 2010, in press. Competing interests The authors declare that they have no competing interests. Authors’ contributions YQS contributed to conception and Selleckchem KPT-8602 design, and gave final approval of the version to be published. ZXW contributed to conception and design. YMY acquired the data and revised the manuscript critically for important intellectual content. YTG acquired the data and drafted the manuscript. YFS acquired the data. XLH and WL contributed to statistic analysis. All authors have read and approved the final manuscript.